SCHEMBL5370712

SCHEMBL5370712

CC1(C)CCc2cccc(N3CCNCC3)c2C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.45
DRD2 P14416 3/20 0.45
DRD3 P35462 3/20 0.45
HTR1A P08908 2/20 0.45
HTR2C P28335 2/20 0.45
DRD4 P21917 1/20 0.45
ADRB1 P08588 6/20 0.43
HTR6 P50406 4/20 0.40
HTR7 P34969 2/20 0.40
HTR3E A5X5Y0 2/20 0.40
HTR3B O95264 2/20 0.40
HTR3A P46098 2/20 0.40
HTR3D Q70Z44 2/20 0.40
HTR3C Q8WXA8 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
HTR2B P41595 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
NCF1 P14598 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374064 0.84 ADRB1 (0.43) HTR2ADRD2DRD3HTR1AHTR2C
SCHEMBL5372181 0.77 ADRB1 (0.46) HTR2ADRD2DRD3HTR1AHTR2C
SCHEMBL5371511 0.76 ALDH1A1 (0.44) ALDH1A1LMNA
SCHEMBL5371145 0.74 HTR2C (0.48) HTR2ADRD2DRD3HTR1AHTR2C
SCHEMBL5366562 0.72 HTR2C (0.49) HTR2ADRD2DRD3HTR1AHTR2C
SCHEMBL5364991 0.71 HTR6 (0.47) HTR2ADRD2DRD3HTR1AADRB1
SCHEMBL18440338 0.70 SRD5A1 (0.45) HTR2ADRD2HTR2CSIGMAR1HTR2B
SCHEMBL5373529 0.69 ADRB1 (0.44) HTR2ADRD2DRD3HTR1AHTR2C
SCHEMBL6261425 0.69 HTR7 (0.51) HTR2AHTR1AHTR2CADRB1HTR6
SCHEMBL7060111 0.68 MAPT (0.65) HTR2ADRD2DRD3HTR1AADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 HTR2A 328/4885DRD2 2/4885DRD3 3/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 HTR2A 328/4885DRD2 2/4885DRD3 3/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 HTR2A 328/4885DRD2 2/4885DRD3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.